CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $96,294, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.12TKRW1.50B · vs all stocks (USD)
Revenue (TTM)
136.00MKRW96.29K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
93.33%vs all stocks
Market Capitalization
2.12TKRW1.50B · vs all stocks (USD)
Enterprise Value
2.41TKRW1.71B · vs all stocks (USD)
Forward P/E
-69.37xvs Biotechnology peers
Price to Book (MRQ)
15.95xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-301.94%vs Biotechnology peers
Return on Assets (TTM)
-8.06%vs Biotechnology peers
Return on Equity (TTM)
-10.49%vs Biotechnology peers
Revenue (TTM)
136.00MKRW96.29K · vs all stocks (USD)
Revenue per Share (TTM)
25.20KRWUpdated Aug 19, 2026Quarterly Revenue Growth
265.80%vs Biotechnology peers
Gross Profit (TTM)
71.10MKRW50.34K · vs all stocks (USD)
EBITDA (TTM)
-7.39BKRW-5.24M · vs all stocks (USD)
Net Income (TTM)
-7.53BKRW-5.33M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
265.80%vs Biotechnology peers
Operating Cash Flow (TTM)
-8.03BKRW-5.69M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-15.74BKRW-11.15M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
699.37MKRWFY2025 · Dec 31, 2025Revenue
14.67BKRWFY2025 · Dec 31, 2025Gross Profit
14.67BKRWFY2025 · Dec 31, 2025Operating Income
-29.97BKRW-21.22M · vs all stocks (USD)
Pre-tax Income
-13.25BKRWFY2025 · Dec 31, 2025Income Tax Expense
2.49BKRWFY2025 · Dec 31, 2025Net Income
-15.74BKRWFY2025 · Dec 31, 2025EBIT
-11.43BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.03BKRWFY2025 · Dec 31, 2025Research & Development
25.65BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
4.31BKRWFY2025 · Dec 31, 2025Other Operating Expenses
934.68MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.05BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.82BKRWFY2025 · Dec 31, 2025EPS (Basic)
-800.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-800.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
19.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
19.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.74BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-4.03BKRWFY2025 · Dec 31, 2025Free Cash Flow
-4.56BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
6.36BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.74BKRWFY2025 · Dec 31, 2025Stock-based Compensation
2.78BKRWFY2025 · Dec 31, 2025Other Non-cash Items
894.01MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.83BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.87BKRWFY2025 · Dec 31, 2025Capital Expenditures
-521.61MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-595.53MKRWFY2025 · Dec 31, 2025Net Acquisitions
-600.03MKRWFY2025 · Dec 31, 2025Purchase of Investments
-206.60BKRWFY2025 · Dec 31, 2025Sale of Investments
102.85BKRWFY2025 · Dec 31, 2025Other Investing Activity
528.11MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-104.35BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
10.12BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-8.85BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-2.93BKRWFY2025 · Dec 31, 2025Other Financing Charges
-539.23MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
120.32BKRWFY2025 · Dec 31, 2025Shares Outstanding
20.30MSharesUpdated Aug 19, 2026Float Shares
14.08MSharesUpdated Aug 19, 2026% Held by Insiders
16.66%vs all stocks
% Held by Institutions
14.27%vs all stocks
Total Cash (MRQ)
108.39BKRW76.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.88KKRWUpdated Aug 19, 2026Total Debt (MRQ)
21.79BKRW15.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1499xvs Biotechnology peers
Current Ratio (MRQ)
147.91xvs Biotechnology peers
Book Value per Share (MRQ)
6.55KKRWUpdated Aug 19, 2026Total Assets
195.37BKRW138.33M · vs all stocks (USD)
Total Current Assets
140.85BKRWFY2025 · Dec 31, 2025Total Liabilities
45.29BKRWFY2025 · Dec 31, 2025Total Non-current Assets
54.51BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
23.96BKRWFY2025 · Dec 31, 2025Total Current Liabilities
21.33BKRWFY2025 · Dec 31, 2025Cash
6.36BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.36BKRWFY2025 · Dec 31, 2025Other Short-term Investments
126.15BKRWFY2025 · Dec 31, 2025Accounts Receivable
5.13BKRWFY2025 · Dec 31, 2025Inventory
396.71MKRWFY2025 · Dec 31, 2025Short-term Debt
4.53BKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.05KKRWFY2025 · Dec 31, 2025Long-term Debt
18.75BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-110.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
10.09BKRWFY2025 · Dec 31, 2025Retained Earnings
-191.59BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
150.08BKRW106.26M · vs all stocks (USD)
52-Week Low
51.75KKRWUpdated Aug 19, 202652-Week High
217.00KKRWUpdated Aug 19, 202652-Week Change
93.33%vs all stocks
50-Day MA
125.81KKRWUpdated Aug 19, 2026200-Day MA
144.95KKRWUpdated Aug 19, 2026Avg 10-Day Volume
333.17KSharesUpdated Aug 19, 2026Avg 30-Day Volume
299.58KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-800.00KRWUpdated Aug 19, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Current ratio is 147.91×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 147.908Industry median: 5.64Industry P95: 23.02Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: 0.00
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 1.26
Consistent revenue growth patternNotable
Growth Consistency Score: 0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $96,294, lower than 95% of all stocks globallySignificant
Revenue (USD): 96,293.655Global P5: 30,274,777.221
Market cap is $1.5B, above the global median of $1.15BNotable
Market cap (USD): 1,500,606,427.796Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nusantara Sawit Sejahtera Tbk
3 interpretationsHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-DecelerationIndustry-Benchmarked ROA and Margin ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Spire Global Inc.
3 interpretationsHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-DecelerationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
D&D Pharmatech Inc.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC